Navigation Links
Misonix Announces Participation in 2nd International Workshop on Focal Therapy
Date:6/25/2009

FARMINGDALE, N.Y., June 25 /PRNewswire-FirstCall/ --Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, participated in the 2nd International Workshop on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held in Noordwijk, The Netherlands, June 10-13, 2009. The meeting was created to address the growing global demand for minimally invasive techniques to ablate urological tumors while maximizing organ preservation. High Intensity Focused Ultrasound and other advanced ablation modalities were featured throughout the program. In addition to the clinical presentations, Misonix exhibited and demonstrated the Sonablate(R) 500 High Intensity Focused Ultrasound ("HIFU") System to the approximately 350 clinicians in attendance.

The Sonablate is a state of the art HIFU instrument used in Europe, Latin America and Asia for trans-rectal ablation of tumors of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.

The company's SonaTherm HIFU System continues to be utilized in clinical evaluations at the University Hospital, Vienna, Austria, for the ablation of certain lesions of the kidney.

For several years, Sonablate's Visually Directed(TM) HIFU has been successfully used in Europe, in an outpatient setting, for whole gland ablation of prostate carcinoma, with minimal incidences of urinary incontinence and reduced reports of erectile dysfunction. Additional studies for the ablation of unifocal and unilateral prostate disease, while maximizing the preservation of surrounding tissue, are underway at University College London Hospitals, London, UK.

"For most men, the current choices for treatment of localized prostate cancer continue to be active surveillance or prostatectomy," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Radical therapy like prostatectomy is often associated with reductions in quality of life due to associated incontinence, impotence, or rectal problems. Visually Directed(TM) HIFU with the Sonablate 500 is a precision technology that is capable of creating localized necrosis in a controllable manner and appears ideal for applications in focal ablation. Additionally, it has been shown to reduce side effects when compared to radical surgery or radiotherapy."

Mr. McManus continued, "We presently distribute the Sonablate 500 from Focus Surgery, Inc. throughout Europe. In addition, we have a worldwide license from Focus Surgery to develop HIFU applications for kidney, liver, and breast disease. Clinical studies are in progress for the treatment of kidney abnormalities. We believe our rights to this technology will position us as an industry leader in the development of multiple products using minimally invasive HIFU technology for the ablation of tumors."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Misonix Contact:             Investor Relations Contact:
    Richard Zaremba              Kevin McGrath
    631-694-9555                 Cameron Associates, Inc.
    invest@misonix.com           212-245-4577
                                 Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
2. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
3. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
4. Misonix Announces Participation in Annual Diabetic Foot Global Conference
5. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
6. Misonix Announces New HIFU Distribution Agreement For Portugal
7. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
8. Misonix Announces New Distribution Agreement for Portugal
9. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
10. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
11. Misonix Announces New Sales Agency Agreement for Eastern Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology: